Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Non-Current Assets (2020 - 2026)

Aura Biosciences filings provide 7 years of Non-Current Assets readings, the most recent being $19.2 million for Q1 2026.

  • Quarterly Non-Current Assets fell 8.19% to $19.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $79.2 million through Mar 2026, down 9.28% year-over-year, with the annual reading at $19.7 million for FY2025, 10.0% down from the prior year.
  • Non-Current Assets hit $19.2 million in Q1 2026 for Aura Biosciences, down from $19.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $27.2 million in Q3 2022 and bottomed at $6.8 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $21.2 million, with a median of $21.9 million recorded in 2024.
  • The largest annual shift saw Non-Current Assets skyrocketed 330.49% in 2022 before it dropped 15.53% in 2024.
  • Aura Biosciences' Non-Current Assets stood at $27.2 million in 2022, then dropped by 14.51% to $23.3 million in 2023, then decreased by 6.02% to $21.9 million in 2024, then dropped by 10.0% to $19.7 million in 2025, then fell by 2.63% to $19.2 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Non-Current Assets are $19.2 million (Q1 2026), $19.7 million (Q4 2025), and $19.9 million (Q3 2025).